(1) 心血管-代谢性疾病分子机制
(2) 新药研发

1、科研项目
（1)我校高层次人才引进经费，2016-08-目前，200万元，在研，主持
（2)国家自然科学基金委，重点项目, 神经氨酸酶作为冠心病治疗新靶标及其抑制剂老药新用的研究，2020-01 至 2024-12，297 万元，在研，参与
（3)国家自然科学基金委，面上项目, STAT1调控血管平滑肌细胞表型在动脉粥样硬化中的作用和机制研究，2017-01-2020.12，57万元，已结题，主持
（4)江苏省“六大人才高峰”高层次人才项目，新型冠状动脉粥样硬化模型小鼠的制备和功能研究，2017-09-2020.08，5万元，已结题，主持
（5)江苏省“双创团队” 项目核心成员，基于Sting信号通路的新型药物研发，65万元，已结题，主持
（6)江苏省特聘教授计划项目（特优）， 基于PDGFRβ-Stat1信号通路的新型纤维化模型小鼠制备和机制研究， 2017-10至2020-09，100万元，已结题，主持
（7)科技部新药创制重大专项，一类多肽新药PD29抗肺纤维临床前开发及纤维化动物模型关键技术研究，300万元，已结题，参与

1.Cai D.C., Liu H.X., Wang J., Hou Y.L., Pang T., Lin H.S., He C.Y.*. Balasubramide derivative 3C attenuates atherosclerosis in apolipoprotein E-deficient mice: role of AMPK-STAT1-STING signaling pathway. Aging (Albany NY). 2021;13(8):12160-12178 (IF: 6.0).
2.Zhen C.L., Liu H.X., Gao L., Tong Y.Y. He C.Y.* Signal transducers and transcriptional activation 1 protects against pressure overload induced cardiac hypertrophy. FASEB J. 2021;35(1):e21240. doi: 10.1096/fj.202000325RRR. (IF: 5.8).
3.Zhou T., Li M.M., Xiao Z.J., Cai J., Zhao W.W., Duan J.J., Yang Z., Guo Z.J., Chen Y.T., Cai W.J., Huang P.P., He C.Y.*, Xu F. *，Chronic Stress-Induced Gene Changes In Vitro and In Vivo: Potential Biomarkers Associated With Depression and Cancer Based on circRNA- and lncRNA-Associated ceRNA Networks。Front Oncol, 2021 Sep 28;11:744251(IF: 5.7).
4.Gao L., Yang T.T., Zhang J.S., Liu H.X., Cai D.C., Wang L.T., Wang J., Li X.W., Gao K., Zhang S.Y., Cao Y.J., Ji X.X., Yang M.M., Han B., Wang S., He L., Nie X.Y., Liu D.M., Meng G., He C.Y.*. THBS1/CD47 Modulates the Interaction of γ-Catenin With E-Cadherin and Participates in Epithelial-Mesenchymal Transformation in Lipid Nephrotoxicity. Front Cell Dev Biol. 2021, 8:601521. doi: 10.3389/fcell.2020.601521. 2020(IF: 6.1).
5.Wang W.W., Smits R., Hao H.P., He C.Y.*. Wnt/β-Catenin Signaling in Liver Cancers. Cancers (Basel). 2019;11(7). pii: E926. doi:10.3390/cancers11070926 (IF: 5.9).
6.Wang L.T., Zhang S.Y., Han J.B., Nie X.Y., Qi Y.J., Han Y.Y., Chen X.，He C.Y.* Activation of STING Pathway Contributed to Cisplatin-Induced Cardiac Dysfunction via Promoting the Activation of TNF-α-AP-1 Signal Pathway. Front Pharmacol. . 2021 Aug 17;12:711238 (IF: 6.0).
7.He C.Y., Medley S.C., Kim J., Sun C.Y., Kwon H.R., Sakashita H., Pincu Y., Yao L.B., Eppard D., Dai B., Berry W.L., Griffin T.M., Olson L.E. STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ. Genes Dev. 2017;15;31(16):1666-1678 (IF: 9.5).
8.He C.Y., Medley S.C., Hu T.S., Hinsdale M.E., Lupu F., Virmani R., Olson L.E. PDGFRβ signalling regulates local inflammation and synergizes with hypercholesterolaemia to promote atherosclerosis. Nat Commun. 2015; 6:7770 (IF: 12.1).
9.He C.Y., Li H.L., Viollet B., Zou M.H., Xie Z.L.. AMPK Suppresses Vascular Inflammation In Vivo by Inhibiting Signal Transducer and Activator of Transcription-1. Diabetes. 2015;64(12):4285-97 (IF: 8.8).
10.He C.Y., Zhu H.P., Li H.L., Zou M.H., Xie Z.L. (2013) Dissociation of Bcl-2–Beclin1 Complex by Activated AMPK Enhances Cardiac Autophagy and Protects Against Cardiomyocyte Apoptosis in Diabetes. Diabetes. 62(4):1270-81 (IF: 8.7).